Analyst Price Targets — CNMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 1, 2025 1:26 pm | Mike Matson | Needham | $61.00 | $57.19 | TheFly | Conmed price target lowered to $61 from $91 at Needham |
| October 4, 2024 9:04 am | Mike Matson | Needham | $97.00 | $66.59 | StreetInsider | Needham Reiterates Buy Rating on CONMED (CNMD) |
| April 25, 2024 9:46 am | Matt O\'Brien | Piper Sandler | $95.00 | $64.34 | StreetInsider | CONMED (CNMD) PT Lowered to $95 at Piper Sandler |
| April 25, 2024 7:28 am | Mike Matson | Needham | $107.00 | $70.01 | StreetInsider | CONMED (CNMD) PT Lowered to $107 at Needham |
| October 26, 2022 8:00 pm | Matt O'Brien | Piper Sandler | $108.00 | $83.39 | TheFly | Conmed price target lowered to $108 from $118 at Piper Sandler |
This site can’t be displayed in an embedded view
Some publishers block loading inside other sites for security reasons. You can open the article in a new tab instead.
Latest News for CNMD

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?

CNMD's growth rests on AirSeal, Buffalo Filter and BioBrace as supply chains normalize, even as tariffs and a GI exit pressure EPS.

Shares of CONMED Corporation (NYSE: CNMD - Get Free Report) have been assigned a consensus recommendation of "Reduce" from the eight ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating

CONMED (NYSE: CNMD) reported fourth-quarter fiscal 2025 sales of $373.2 million, representing a 7.9% year-over-year increase as reported and 7.1% growth in constant currency, as management emphasized continued progress in orthopedics and improved supply conditions. For the full year, sales were $1.375 billion, up 5.2% as reported and 5.1% in constant currency. President and CEO Pat

CNMD posts strong fourth-quarter 2025 results with EPS and revenue beat, driven by surgical growth and improved gross margin.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CNMD.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
